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MaOBJECTIVES This paper reviews the published data and reports 3 cases of thrombosis involving CoreValve (Medtronic,
Minneapolis, Minnesota) and 1 involving Edward Sapien (Edwards Lifesciences, Irvine, California) devices. Three of these
cases had pathological ﬁndings at autopsy.
BACKGROUND Only a limited number of cases of valve dysfunction with rapid increase of transvalvular aortic gradients
or aortic insufﬁciency post-transcatheter aortic valve replacement (TAVR) have been described. This nonstructural
valvular dysfunction has been presumed to be because of early pannus formation or thrombosis.
METHODS Through reviews of the published reports and 4 clinical cases, pathological and clinical ﬁndings of early valve
thrombosis are examined to elucidate methods for recognition and identifying potential causes and treatments.
RESULTS This paper presents 4 cases, 2 of which had increasing gradients post-TAVR. All 3 pathology cases showed
presence of a valve thrombosis in at least 2 TAV leaﬂets on autopsy, but were not visualized by transthoracic echocar-
diogram or transesophageal echocardiogram. One case was medically treated with oral anti coagulation with normali-
zation of gradients. The consequence of valve thrombosis in all 3 pathology patients either directly or indirectly played a
role in their early demise. At least 18 case reports of early valve thrombosis have been published. In 12 of these cases, the
early treatment with anticoagulation therapy resolved the thrombus formation and normalized aortic pressures gradients
successfully.
CONCLUSIONS These 4 cases elucidate the occurrence of valve thrombosis post-TAVR. Consideration should be given
to treatment with dual antiplatelet therapy and oral anticoagulation in patients post-TAVR with increasing mean pressure
gradients and maximum aortic valve velocity. Further research should be conducted to create guidelines for antith-
rombotic therapy following TAVR procedure. (J Am Coll Cardiol Intv 2015;8:728–39) © 2015 by the American College of
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AB BR E V I A T I O N S
AND ACRONYM S
AI = aortic insufﬁciency
AS = aortic stenosis
AVA = aortic valve area
COPD = chronic obstructive
pulmonary disease
NYHA = New York Heart
Association
Pmean = mean pressure
gradient
SAVR = surgical aortic
valve replacement
SOV = sinus of Valsalva
STS = Society of Thoracic
Surgeons
TAVR = transcatheter aortic
valve replacement
TTE = transthoracic
echocardiogram
Vmax = maximum aortic valve
velocity
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729valve replacement (SAVR) (1,4–10). Although limited
TAVR procedures to date have shown a similar rate of
failure to those individuals treated with surgical aortic
valve (11–14). However, there has been insufﬁcient
time to track full outcomes of TAVR procedures ($5
years) due to the introduction and approval of this pro-
cedure spanning just over a decade.
Only a limited number of cases of early valvular
dysfunction with rapid increase of transvalvular
aortic gradients or aortic insufﬁciency (AI) have been
described (15–17). These valve failures have been
presumed to be because of either early pannus for-
mation or thrombosis. This paper reviews the pub-
lished data and reports 4 additional cases, of which
3 had further autopsy pathology reports. The ﬁrst
patient treated with a CoreValve bioprosthesis
(Medtronic, Inc., Minneapolis, Minnesota) manifested
with early post-procedure elevation in transvalvular
gradient and insufﬁciency, requiring treatment with
a second valve-in-valve TAVR (Figure 1). In 2 other
patients, valve failure was noted at autopsy. The pa-
tient that underwent the valve-in-valve procedure
died 1 month after the procedure, and an autopsy was
performed that elucidates the mechanisms of early
valvular failure, whereas the other 2 died 48 days
(Sapien, Edwards Lifesciences, Irvine, California) and
15 days (CoreValve) after the procedure. The last case
had post-TAVR severe AS 10 months following im-
plantation (CoreValve) that was treated medically
with oral anticoagulation.
CASE SERIES
CASE 1. In i t ia l TAVR procedure . A 68-year-old
woman presented with symptomatic severe AS, with
a previous medical history of congestive heart failure,
moderate chronic obstructive pulmonary disease
(COPD), stage IV chronic kidney disease, chronic iron
deﬁciency anemia, and a New York Heart Association
(NYHA) functional class III. The patient had been
deemed inoperable by 4 cardiac surgeons because
of a calciﬁed ascending aortic root. The patient’s
screening transthoracic echocardiogram (TTE) re-
vealed severe AS with a calculated mean pressure
gradient (Pmean) of 43.5 mm Hg, a maximum aortic
valve velocity (Vmax) of 4.3 m/s, and an aortic valve
area (AVA) of 0.4 cm2. Her calculated Society of
Thoracic Surgeons (STS) mortality score was 4%, and
her EuroSCORE (European System for Cardiac Oper-
ative Risk Evaluation) was 3.5%. There were
no unusual ﬁndings regarding the aortic root’s char-
acteristics, with normal size sinus of Valsalva (SOV),
that would predispose to a thrombotic setting.
Under general anesthesia, she underwent a successfulTAVR, with a 26-mm CoreValve bioprosthesis
implanted through a left subclavian approach
due to severe peripheral vascular disease.
The valve was mounted by usual character-
istics and deployed by ﬂuoroscopy guidance
on the ﬁrst attempt with an implantation
depth of 8 mm. There was no evidence of AI
and post-dilation was not considered neces-
sary. On follow-up TTE, there was evidence
of mild AI.
Post-TAVR TTE measurements revealed a
Pmean of 16 mm Hg, a Vmax of 2.8 m/s, and an
AVA of 1.3 cm2. The patient had a 5-day hos-
pital stay in which she had worsening anemia,
with a hemoglobin decrease from 11.9 mg/dl to
8.6 mg/dl, requiring a transfusion of 2 units of
packed red blood cells. She also developed
transient thrombocytopenia, with a platelet
count of 6  103 platelets/ml. A possible
heparin-induced thrombocytopenia was sus-
pected, so heparin and clopidogrel were dis-
continued. Platelet factor 4 was ordered, and
the results were negative. On discharge, the TTE
values were in normal ranges with a Pmean of 15.1
mm Hg, a Vmax of 2.7 m/s, and an AVA of 1.3 cm2. The
patient was discharged home on antiplatelet mono-
therapy of aspirin 81 mg/day due to her bleeding risk.
1-month fo l low-up . At 1-month follow-up post-
TAVR, the patient referred to be “feeling better,” but
still required oxygen support because of her COPD.
Her NYHA functional class improved from III to II.
Her cardiovascular physical examination revealed an
aortic outﬂow murmur, with preserved second heart
sounds and no indication of AI. TTE revealed an in-
crease in Pmean to 43 mm Hg, as well as an increase in
Vmax to 4.3 m/s, and a decrease of the AVA to 0.5 cm2.
Mild perivalvular AI was seen on TTE. Although a
high transvalvular velocity was documented, the
clinical presentations showed improvement and the
physical examination did not support the echocar-
diographic ﬁndings. Because the patient’s symptoms
were improved, she was followed up clinically and
continued on the same antiplatelet monotherapy.
6-month fo l low-up. At 6-month follow-up, there
was worsening of the NYHA functional class to III.
The patient’s TTE revealed a Pmean of 50 mm Hg, a
Vmax of 4.6 m/s, and an AVA of 0.6 cm2, with mod-
erate AI. The patient was evaluated with a cardiac
catheterization that conﬁrmed moderate to severe AS
of the bioprosthesis as well as a 2þ AI with a central
jet. The CoreValve dysfunction was presumed to be
from early pannus formation. On the basis of hemo-
dynamic evidence of early valve failure, it was
decided to perform a valve in valve TAVR.
FIGURE 1 Case 1
(A) Gross image of overlapped CoreValve prostheses, aortic view shows the inner valve (second valve) and red arrows indicate adherent mural
thrombus on surfaces of right coronary cusp (RCC) and noncoronary cusp (NCC). (B) Excised outer valve leaﬂets (ﬁrst valve) are intact and the
aortic surface shows presence of focal thrombus (red arrows). (C) For the ﬁrst valve, NCC shows organizing ﬁbrin thrombus (Th) on the aortic
surface near commissural attachment site. (D, E) For the second valve, gross images for the pericardial leaﬂets are viewed from the aortic (D)
and ventricular surfaces (E) with red arrows pointing to the presence of thrombus. (F, G, H) For the second valve, low-power images of NCC,
RCC, and left coronary cusp (LCC) show that pericardial valve leaﬂets are intact and there is a layered ﬁbrin thrombus on aortic surfaces of NCC
and RCC. (I, J, K) Lower rows show high-power magniﬁcation of each boxed area from all 3 leaﬂets with thrombus overlying the valve leaﬂets.
Images C, F, G, H, I, and K are stained with Movat pentachrome, and J is stained with hematoxylin and eosin.
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730Second TAVR procedure . A transesophageal echo-
cardiogram was performed before the second TAVR
implantation, revealing a nodular thickening at the
aortic side of the CoreValve leaﬂet (Figure 1).
The second valve was also a 26-mm CoreValve
bioprosthesis implanted through a left subclavian
approach. The valve was mounted by usual charac-
teristics and deployed by ﬂuoroscopy guidance on the
ﬁrst attempt with an implantation depth of 4 mm.
Post-dilation was not considered necessary.
Post-implantation measurements under ﬂuoros-
copy revealed no signiﬁcant AS, no residual AI, and a
Pmean of 9 mm Hg. TTE performed the day followingthe second TAVR procedure, showed a Pmean of
20 mm Hg, a Vmax of 3.02 m/s, and an AVA of 1.5 cm2.
These values indicate a resolution of her severe AS.
The patient underwent an uneventful post-operative
stay and was discharged home on day 3.
The patient was discharged home on antiplatelet
therapy of clopidogrel at the time of TAVR and
remained on therapy until her death. Following
discharge, the patient returned to her daily activities,
and her AS symptoms had signiﬁcantly improved.
Sixteen days after the second valve implantation, the
patient developed nausea and vomiting for 24 h due
to food poisoning and had a witnessed sudden cardiac
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731death. An autopsy was performed to determine the
cause of death.
Autopsy ﬁndings . Valve-in-valve Medtronic Core-
Valve devices were visualized in the aortic position
and calciﬁcation of the underlying native aortic valve
leaﬂets was noted with mild left coronary artery
calciﬁcation. The heart weighed 538 g with attached
aortic arch. There was evidence of left ventricular
hypertrophy, with no evidence of myocardial ﬁbrosis
or necrosis. The coronary arteries revealed mild to
moderate hemodynamically insigniﬁcant coronary
artery disease.
The inner CoreValve (second valve) appeared well
seated without paravalvular leaks. The valve leaﬂets
showed the presence of mural thrombus on the aortic
surface involving the right and the noncoronary
leaﬂets, which limited their mobility (Figure 1). The
left coronary cusp was freely movable and there was
an absence of valve calciﬁcation or thrombus. The
coronary ostia were wide open. Histologically, the
noncoronary and the right aortic leaﬂets showed
presence of organizing ﬁbrin thrombus on the aortic
surface near the commissural attachment site with
the underlying valve pericardial collagen intact,
without degeneration. Scattered, minimal fragments
of ﬁbrin thrombus were adherent to the left coronary
cusp. Mild inﬂammatory inﬁltrate was noted and
consisted of a single to a few layers of palisading
macrophages, lymphocytes, and rare neutrophils
focally lining the leaﬂet surfaces and were located
beneath the valve thrombus (Figure 1). The outer
CoreValve (ﬁrst valve) showed the presence of
thrombus in the area of the valve leaﬂets, which
were compressed on the valve frame. Sections of
the valve leaﬂets did not show any presence of a
pannus but organizing thrombus on all 3 leaﬂets
without inﬂammation or degeneration; however,
the noncoronary leaﬂet showed signiﬁcantly larger
thrombus (Figure 1).
The autopsy revealed evidence of severe COPD,
hypertensive changes in the kidneys, and fatty
changes in the liver. There was no evidence of sys-
temic or pulmonary emboli.
CASE 2. An 88-year-old woman presented with
symptomatic severe AS with a history of coronary
artery disease with stenting of the left circumﬂex
artery, atrial ﬂutter with pacemaker implantation,
hypertension, hypercholesterolemia, breast cancer,
COPD, and cerebrovascular disease with possible
transient ischemic attack and post-carotid endarter-
ectomy. The screening TTE revealed severe AS with a
calculated Pmean of 59.7 mm Hg, an aortic AVA of
0.61 cm2, and left ventricular ejection fraction of60%. The STS mortality score was 8.3%. There were
no unusual ﬁndings regarding the aortic root’s char-
acteristics, with normal size SOV, that would predis-
pose to a thrombotic setting. The patient underwent a
successful transfemoral TAVR, with a 23-mm Edwards
Sapien aortic valve, with an immediate post-
procedure Pmean of 9 mm Hg. There was presence of
trace AI and post-dilation was performed with an
additional 1 cc of contrast added to the balloon due to
a paravalvular leak.
On follow-up the patient’s symptoms had
improved to NYHA functional class I; Pmean remained
9 mm Hg; and the valve appeared to function nor-
mally on TTE. The patient was prescribed dual anti-
platelet therapy (aspirin and clopidogrel) at the time
of TAVR and remained on therapy until her death due
to a cerebral hemorrhage 48 days later.
Autopsy ﬁndings . An Edwards Sapien aortic valve
was present in the aortic position without any
fracture, but with underlying native aortic valve
calciﬁcation. Only the Edwards Sapien valve, the
surrounding aorta, and underlying native aortic valve
were received for evaluation. The valve appeared to
be well seated in the aortic root although the frame
had been previously opened along the anterior
aspect. The native aortic valve showed calciﬁcation
beneath the frame. Both the left and right coronary
ostia were widely patent. There were no paravalvular
gaps. The valve leaﬂets were generally pliable, with
the exception of the noncoronary cusp, which
demonstrated compromise of the mobility due to
thrombus covering 90% of the aortic surface of the
valve leaﬂet (Figure 2). The left coronary cusp also
showed basal deposition of thrombus on the aortic
surface, which covered only 20% of the valve leaﬂet.
There was mild platelet-ﬁbrin thrombus adherent on
the aortic surface of the right coronary cusp near the
commissure. No cusp tears or perforations were
identiﬁed. On the ventricular surface, mild adherent
platelet-ﬁbrin thrombi were seen as well as mild focal
chronic inﬂammation composed of macrophages and
lymphocytes, which were observed on all 3 valve
leaﬂets on the aortic and ventricular surfaces.
CASE 3. A 90-year-old man presented with calciﬁc
severe AS. The patient presented with dyspnea
and had NYHA functional class III for a duration of
6 months. The patient’s ejection fraction had deteri-
orated signiﬁcantly within the weeks leading to his
TAVR and had worsened from 30% to 15% to 20% at
the time of TAVR. Aortic root anatomy appeared
normal with normal size SOV. He underwent a suc-
cessful transfemoral TAVR, with a 29-mm Medtronic
CoreValve bioprosthesis. The valve was mounted by
FIGURE 2 Case 2
(A) Radiograph of Edwards Sapien prosthesis following removal of the valve along with the aorta and the outﬂow tract and cutting open the
transcatheter valve at autopsy. (B, C) Gross images show stented valve excised with aortic root (aortic surface at left; ventricular surface at
right). Note presence of a tan-white thrombus (red arrow) is shown on the aortic surface of the NCC. (D) A large platelet ﬁbrin thrombus on
aortic surface of NCC involving entire cusp. (E) LCC shows a valve thrombus on aortic surface near the basal attachment site. (F) Focal ﬁbrin
thrombus attached to ventricular surface of RCC. (G, H) High-power images show the interface between thrombus and the pericardial valve.
Images D, E, F, and G are stained with Movat pentachrome, and H is stained with hematoxylin and eosin. Abbreviations as in Figure 1.
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732usual characteristics and deployed by ﬂuoroscopy
guidance on the ﬁrst attempt. There was no evidence
of AI and post-dilation was not considered necessary.
The patient was on dual antiplatelet therapy
(aspirin and clopidogrel) during and following
the TAVR procedure. The initial Pmean post-TAVR
implantation was 5.7 mm Hg. One hour post-
operatively, the patient lost sensation and move-
ment on his left side, and a computed tomography
scan demonstrated a left occipital cerebral infarction.
He had a previous history of a right occipital cerebral
infarction following a coronary artery bypass graft20 years previously. On day 7, Pmean increased to
7.3 mm Hg, although ejection fraction increased from
w20% to 30%. The patient subsequently developed
pneumonia and expired 15 days post-implantation.
Autopsy ﬁndings . The CoreValve device was pre-
sent in aortic position with severe underlying calci-
ﬁcation of the native aortic valve leaﬂets and marked
mitral annular calciﬁcation (Figure 3). Pacemaker
leads were present in the right ventricle and right
atrial appendage. The heart weighed 675 g including
the ascending aorta. There was a C-shaped mitral
annular calciﬁcation with extension onto the anterior
FIGURE 3 Case 3
(A) Radiograph of CoreValve prosthesis and surgical clips can be seen from the previous bypass graft procedure. (B) Gross image of aortic
surface of CoreValve. Note the thrombus present on aortic surface of the valve cusps is greater on RCC (red arrow) than LCC and NCC. (C)
Excised valve cusps, aortic views. Red arrow indicates adherent mural thrombus on surfaces of RCC. (D) RCC with organizing ﬁbrin thrombus on
aortic surface. (E) NCC with mild ﬁbrin thrombus on aortic surface. (F) LCC with organizing ﬁbrin thrombus on aortic surface. Images D, E, and F
are stained with Movat pentachrome. Abbreviations as in Figure 1.
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733mitral valve leaﬂet. The stent frame did not show any
coverage by intimal tissue above the valve cusps.
Valve leaﬂets are brown-tan with roughened surfaces
and adherent dark red blood clot and ﬁbrin, pre-
dominantly on aortic surfaces (Figure 3). The valve
appeared well positioned without grossly apparent
paravalvular gaps; however, the valve leaﬂets had
limited mobility and sections of the CoreValve leaf-
lets show ﬁbrin thrombus, predominantly on aortic
surfaces and to a lesser extent on ventricular sur-
faces, on all valve leaﬂets (Figure 3). The right coro-
nary cusp had the largest amount of thrombus with
areas of palisading macrophages seen on all 3 valve
cusps, more on the aortic side than the ventricular
side.
CASE 4. An 85-year-old woman presented with
symptomatic severe AS and NYHA functional class IIIwith a history of hypertension, peripheral vascular
disease, and mild COPD. The screening TTE revealed
severe AS with a calculated Pmean of 43 mm Hg and
left ventricular ejection fraction of 35%. Calculated
STS mortality score was 7.7%. The SOV diameter was
more than adequate to accommodate a 29-mm valve.
There was only mild to moderate calcium at the
leaﬂet level and the SOV area did not have any cal-
cium. There was ﬂuoroscopic evidence of annular
calcium that was not considered of great concern. The
patient underwent a successful transfemoral TAVR,
with a 29-mm Medtronic CoreValve bioprosthesis,
with an immediate post-procedure Pmean of 9 mm Hg.
The placement of the valve was achieved with the
ﬁrst attempt and deployed at an average depth of
6 mm with no need for post-dilation. Immediate
paravalvular leak was mild on transesophageal
echocardiogram and mild on aortic root injection.
FIGURE 4 Case 4 Post-TAVR Progressive Pmean Across Time
An increase is noted in the ﬁrst 2 months with a marked increase at 6 and 9 months post-transcatheter aortic valve replacement (TAVR). Three
months after initiation of anticoagulation therapy, mean pressure gradients (Pmean) normalized.
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734The patient was discharged with dual antiplatelet
therapy for 3 months followed by monotherapy with
ASA. At 1-month follow-up, the patient’s symptoms
had improved to NYHA functional class I and Pmean
increased to 22.5 mm Hg. From a clinical standpoint,
the patient’s symptoms had improved. On TTE per-
formed 6 months after TAVR, there was a marked in-
crease in Pmean to 42 mm Hg. During the following 3
months, the Pmean values remained high (as seen in
Figure 4). Due to the possibility of valve thrombosis,
the patient was placed on oral anticoagulation with
warfarin,which consequently led to a decrease in Pmean
values with complete normalization 3 months later.
The clinical course of the patient remained uneventful
and symptom free on anticoagulation therapy.
CASE REPORTS OF TRANSCATHETER AORTIC
VALVE THROMBOSIS
At least 18 case reports of early valve thrombosis
have been published (Table 1). The mean age of pre-
sentation was 79  5 years. Eleven patients (61.1%)
were male, whereas 5 (31.2%) were female. Two
case reports did not describe sex characteristics.
There are 17 Edwards Sapien TAV bioprostheses and
1 Medtronic CoreValve bioprosthesis that developed
increasing gradients from 3 days to 24 months
post-implantation. TTE evidence of thrombosisrestricting the TAV leaﬂet mobility was suggested in
the majority of cases dictating treatment. Twelve of
the 18 patients were treated with varying anti-
coagulation therapy with either heparin or warfarin,
or a combination. Nine of those 12 patients had a
decrease in Pmean and had symptomatic improve-
ment or were asymptomatic (16–21). One patient was
treated with dual antiplatelet therapy and had symp-
tomatic relief (22). Three patients had retrieval of
the TAVR bioprosthesis followed by SAVR with
further pathology workup that showed thrombus
formation (15,23,24). In case 4, even though there was
no evidence of TAV thrombosis, the increase in Pmean
suggested a valve dysfunction that was treated
successfully with oral anticoagulation.
DISCUSSION
Our current understanding of TAVR post-
implantation management is based on the history
and outcomes of SAVR. The recommendations pro-
posed to cover treatment for SAVR have assisted in
establishing guidelines for percutaneous interven-
tional treatments. Post-TAVR dysfunction can be
divided into 2 groups, structural valve deterioration
and nonstructural dysfunction (11). Structural valve
deterioration is related to changes within the valve
and its adjoining structures, whereas nonstructural
TABLE 1 Case Reports of TAV Thrombosis
Case # First Author (Ref. #)
Patient
Characteristics
Type of THV*
Follow-Up After TAVR
Antiplatelet Therapy
After TAVR Treatment Outcome/HistologyAge, yrs Sex Duration Symptom Examination
1 Trepels et al. (15) 84 Female Edwards Sapien,
23 mm
8 months Dyspnea Mean PG: 11 to 53 mm Hg
TEE: restricted leaﬂet
mobility
DAPT discontinued
after 6 weeks
THV retrieval and
SAVR
Thrombus with ﬁbrous
organization.
Thrombophilia screen: mild
protein S reduction,
positive cold agglutinin
2 Kefer et al. (16) 78 Male Edwards Sapien,
26 mm
4 months NSTEMI; CHF Mean PG: 15 to 72 mm Hg
ICE/TTE: thrombus
on leaﬂets
DAPT, clopidogrel
stopped after
1 month
Heparin followed
by warfarin
Mean PG decreased to
22 mm Hg
Thrombophilia screen:
negative
3 Pergolini et al. (17) 87 Male Edwards Sapien XT,
29 mm
8 months Dyspnea
NYHA I to III
Mean PG: 8 to 50 mm Hg
TEE: restricted leaﬂet
mobility with thrombus
DAPT, clopidogrel
stopped at 3
months, then
restarted after
4 months
Anticoagulation
(heparin followed
by warfarin)
Asymptomatic
Mean PG decreased to
9 mm Hg
4 Greason et al. (23) 74 Female Edwards Sapien,
23 mm
2 weeks Dyspnea
NYHA I to III
Mean PG increased to
43 mm Hg
Echo: restricted leaﬂet
mobility with thrombus
Aspirin THV retrieval
and SAVR
Discharged after long
hospitalization.
Mean PG decreased to
15 mm Hg
Histology: organizing
thrombosis
5 Cota et al. (19) 80 Male Edwards SAPIEN
XT, 23 mm
10 months Dyspnea
NYHA I to III
Mean PG increased to
54 mm Hg
TEE: Suspected thrombotic
fusion of two THV leaﬂets
DAPT Anticoagulation
(OAT)
Asymptomatic
Mean PG decreased to
13 mm Hg
Thrombophilia screen:
negative
6 Cota et al. (19) 81 Male Edwards Sapien
XT, 23 mm, in
Carpentier
Edwards, 25 mm
4 months Dyspnea
NYHA I to III
Mean PG increased to
51 mm Hg
TEE: suspected thrombotic
fusion of 2 THV leaﬂets
NA Anticoagulation
(OAT)
Asymptomatic
Mean PG decreased to
9 mm Hg
7 Cota et al. (19) 74 Female Edwards Sapien XT,
26 mm
2 months Dyspnea
NYHA I to II
Mean PG increased to
34 mm Hg
TEE: Suspected thrombotic
apposition of THV
leaﬂets
DAPT Anticoagulation
(OAT)
Asymptomatic
Mean PG decreased to
9 mm Hg
8 Latib et al. (20) 83 Male Edwards Sapien XT,
26 mm
6 months Dyspnea
NYHA I to II
Mean PG increased to
68 mm Hg
TEE: restricted leaﬂet
mobility without
thrombus
DAPT Anticoagulation
(OAT)
Asymptomatic
Mean PG decreased to
11 mm Hg
9 Latib et al. (20) 81 Male Edwards Sapien XT 15 months Dyspnea
NYHA I to III
Mean PG increased to
45 mm Hg
DAPT, clopidogrel
stopped after
3 months
Anticoagulation
(OAT)
Symptomatic improvement
Mean PG decreased to
19 mm Hg
10 Latib et al. (20) 83 Male Edwards Sapien
XT, 26 mm
24 months Dyspnea
NYHA I to III
Mean PG increased
to 37 mm Hg
NA Anticoagulation
(OAT)
Symptomatic improvement
Mean PG decreased to
13 mm Hg
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TABLE 1 Continued
Case # First Author (Ref. #)
Patient
Characteristics
Type of THV*
Follow-Up After TAVR
Antiplatelet Therapy
After TAVR Treatment Outcome/HistologyAge, yrs Sex Duration Symptom Examination
11 Al-Rashid et al. (22) 72 Male Edwards Sapien 6 months Dyspnea
NYHA II to III
TEE: thickened restricted
THV leaﬂets without
thrombus
Discontinuing DAPT
after 4 months
DAPT Symptomatic improvement
12 Tay et al. (18) 66 Male Edwards Sapien,
23 mm
3 days Cardiac arrest TEE: thrombus on the THV
at post-implantation
DAPT Heparin continued
post-TAVR
Deceased
Autopsy: normal THV
position and good
leaﬂet mobility with
thrombi on the stent
frame
13 Tay et al. (18) 77 Female Edwards Sapien,
26 mm, within
MVR
1 month Dyspnea TEE: thrombus on
edge of THV
DAPT Anticoagulation Discharged home
14 Lancellotti et al. (24) 86 Male Medtronic CoreValve,
26 mm
12 months Dyspnea
NYHA I to III
Mean PG increased to
41 mm Hg
TEE: thickened restricted
THV leaﬂets without
thrombus
DAPT, clopidogrel
stopped at
3 months
THV retrieval
and SAVR
Discharged after long
hospitalization
Histology: pannus
restricting leaﬂet
mobility with thrombus
15 Pache et al. (21) 86 Male Edwards Sapien XT,
29 mm
7 days NA CTA: Restricted leaﬂet
mobility with thrombus
(incidental)
DAPT Anticoagulation
(warfarin)
Complete disappearance of
cusp thrombus
16 Leetmaa et al. (29) NA NA Edwards Sapien XT,
29 mm
1 month Bleeding
problems
NA DAPT, started
monotherapy
after 1 month due
to bleeding
problems
NA Deceased on day 106
Autopsy: thickened, stiff
and with ﬁbrosis on
both sides of the
leaﬂets
17 Leetmaa et al. (29) NA NA Edwards Sapien XT,
29 mm
1 month Bleeding
problems
NA DAPT, started
monotherapy
after 1 month due
to bleeding
problems
NA Deceased on day 137
Autopsy: thickened, stiff
and with ﬁbrosis on
both sides of the
leaﬂets
18 Orbach et al. (30) 81 Female Edwards Sapien,
26 mm
21 months Heart failure Mean PG increased to
53 mm Hg
TTE: thickened and
restricted prosthetic
aortic-valve leaﬂets
Aspirin Enoxaparin and
warfarin
Symptomatic improvement
Mean PG decreased to
10 mm Hg
Case Series Autopsy Cases
1 CVPath Institute 68 Female Medtronic
CoreValve, 26 mm,
in CoreValve,
26 mm
First: 6 months
Second: 17 days
Dyspnea
NYHA II to III
First: Mean PG; 16
to 50 mm Hg
Aspirin Death Cardiac death
(valve thrombosis)
2 CVPath Institute 88 Female Edwards Sapien,
23 mm
48 days Dyspnea
NYHA I
Mean PG: 9 mm Hg
(same as immediate
post-implantation).
Valve appeared to function
normally on TTE
DAPT Death Noncardiac death
(cerebral bleed)
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737dysfunction includes components not directly asso-
ciated with the valve such as a pannus or paravalvular
aortic regurgitation (11).
Thrombotic stenosis of an aortic valve bioprosthesis
after surgical replacement is an unusual complication
(25–27). The incidence of bioprosthetic thrombosis
is 0.03% per year (26). This frequency may be under-
estimated because early echocardiographic assess-
ments are not routinely done. As mentioned in
the review of the published reports, treatment for
bioprosthetic thrombosis ranges from surgery to
thrombolysis and oral anticoagulation (25,27).
During the presentation of these cases, there were
no guidelines to base a proper treatment for valve
dysfunction secondary to early thrombosis. Different
mechanisms of thrombus formation after TAVR, such
as pertinent antithrombotic treatment, suboptimal
stenting due to valve malposition, and coagulation
disorders that predispose patients to thrombus for-
mation, have been described (15,17,18,23,24). In cases
1 and 4, there was evidence of rapid early increase in
transvalvular gradients evidenced on TTE, although
there was no direct visualization of valve thrombosis.
Pathology work-up in case 1 revealed valve throm-
bosis. In cases 2 and 3, even though pathology work-
up revealed evident valve thrombosis, there was no
evidence of valve dysfunction clinically or with TTE,
probably due to the short period—48 and 15 days—the
patients lived following TAVR. Because there was no
evidence of bioprosthesis cusp calciﬁcations in either
of the 3 cases with pathology work-up, structural
deterioration or obvious morphological abnormalities
of the valves was unlikely (25). In case 1, because the
second inner CoreValve bioprosthesis skirt acted as a
barrier to the outer CoreValve bioprosthesis, the
thrombi seen in both valves may suggest a patient
predispositioned to thrombus formation.
All leaﬂets from these 3 autopsy cases where
re-reviewed to reconﬁrm the absence of microinjury
or leaﬂet degeneration that may have been present
at the time of implantation. Therefore, it is unlikely
that valve thrombosis was caused by leaﬂet injury.
Furthermore, the aortic surface of the valve leaﬂets
with thrombosis revealed macrophage presence un-
derneath the thrombus. A mildly greater inﬂamma-
tory cell inﬁltrate was observed in the Edwards
Sapien valve. Pathology review also revealed the
presence of many inﬂammatory cells within the
thrombus, therefore it is likely that the valve leaﬂet
was not the culprit. There was no indication of
excessive lymphocytic inﬁltrate that would suggest
an autoimmune rejection.
There are no clinically tested guidelines describing
appropriate therapy following thrombus formation.
PERSPECTIVES
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738Although the cause of thrombus formation in case 1
could have been from the lack of dual antiplatelet
therapy after the procedure, another potential cause
could be a possibly unrecognized hypercoagulable
state. It is important to note that although the patients
in cases 2 and 3 had been on dual antiplatelet therapy
right after TAVR, both developed valve thrombosis.
Current antiplatelet therapy recommendations af-
ter CoreValve bioprosthesis implantation consist of
dual antiplatelet therapy with clopidogrel and aspirin
for the ﬁrst 6 months, and then continuous use of as-
pirin (16). Conversely, in 1 study, there was no signiﬁ-
cant difference seen between groups treated with dual
antiplatelet therapy versus aspirin alone after TAVR
(28). Further consideration could be given to detec-
tion of thrombosis on computed tomography (21).
A diagnosis of valve thrombosis must be consid-
ered with a progressive increase in transvalvular
gradients and reappearance of symptoms (17). It is
important to clarify that an increase in Pmean can
range from days to months. From our 3 cases and
subsequent review of the published reports, in cases
of early valve dysfunction, oral anticoagulation
treatment should be started regardless of a visualized
thrombus on TTE (16–21).At least 18 case reports of early valve thrombosis with
development of increasing gradients while on antith-
rombotic therapy have been previously published with
little consensus on or scientiﬁc inquiry into the
appropriate treatment. This study adds pathologic
conﬁrmation of thrombus and pannus formation in
cases with a progressive increase in transvalvular
gradients along with anecdotal success of dual anti-
platelet therapy and oral anticoagulation in patients
with increasing TTE aortic gradients. Clinically tested
guidelines describing appropriate antithrombotic
therapy following thrombus formation are needed to
improve our knowledge base.CONCLUSIONS
The 4 cases discussed elucidate the occurrence of
valve thrombosis post-TAVR, following 3 CoreValve
replacements at 15 days, 7 months, and 10 months
and 1 Edward Sapien valve at 48 days. As reported in
the 4 cases, thrombus formation presenting as ste-
nosis of a TAVR bioprosthesis was detected days
to months after implantation. Several of the pub-
lished reports reviewed cases and 2 of our 4 cases
elucidated an increase in transvalvular gradient.
Although not clearly demonstrated in all 4 cases, this
ﬁnding suggests that rapid change in Doppler-derived
estimates in transvalvular gradients may be ahallmark of valve thrombosis even without clinical
symptoms. The frequency of thrombosis post-TAVR
may be underestimated because clinical signs could
be masqueraded by comorbidities. Another reason for
possible underestimation of the frequency is that
early echocardiographic assessments are not uni-
formly done on follow-up. Our ﬁndings indicate that
consideration should be given to treatment with dual
antiplatelet therapy and oral anticoagulation in a
patient’s post-TAVR with increasing Pmean and Vmax
and decreasing AVA. Valve-in-valve TAVR or SAVR
can be performed if attempts to dissolve the clot are
not successful. Current antithrombotic therapy post-
TAVR is empirically based on presumed thrombotic
milieu and patient observation. Further research
should be conducted to create guidelines for antith-
rombotic therapy following TAVR procedures.
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